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Summary Tumour angiogenesis is a complex multistep process regulated by a number of angiogenic factors.
One such factor, platelet-derived endothelial cell growth factor has recently been shown to be thymidine
phosphorylase (TP). TP catalyses the reversible phosphorylation of thymidine to deoxyribose-1-phosphate and
thymine. Although known to be generally elevated in tumours, the expression of this enzyme in breast
carcinomas is unknown. Therefore, we used ribonuclease protection assays and immunohistochemistry to
examine the expression of TP in 240 primary breast carcinomas. Nuclear and/or cytoplasmic TP expression was
observed in the neoplastic tumour epithelium in 53% of tumours. Immunoreactivity was also often present in
the stromal, inflammatory and endothelial cell elements. Although endothelial cell staining was usually focal,
immunoreactivity was observed in 61% of tumours and was prominent at the tumour periphery, an area where
tumour angiogenesis is most active. Tumour cell TP expression was significantly inversely correlated with grade
(P = 0.05) and size (P = 0.003) but no association was observed with other tumour variables. These findings
suggest that TP is important for remodelling the existing vasculature early in tumour development, consistent
with its chemotactic non-mitogenic properties, and that additional angiogenic factors are more important for
other angiogenic processes like endothelial cell proliferation. Relapse-free survival was higher in node-positive
patients with elevated TP (P =0.05) but not in other patient groups. This might be due to the potentiation of
chemotherapeutic agents like methotrexate by TP. Therefore, this enzyme might be a prediction marker for
response to chemotherapy.
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Angiogenesis is the formation of new vessels from the existing
vascular bed (Blood and Zetter, 1990). It is a complex
multistep process that is usually tightly regulated and only
activated transiently as in reproduction and wound healing.
Sustained angiogenesis is observed during pathological
conditions like the vascularisation of tumours. Indeed,
tumours cannot grow beyond 2-3 mm diameter without
eliciting such a blood supply (Folkman, 1990). Induction of
angiogenesis is mediated by an increasing number of
angiogenic peptides (Bicknell and Harris, 1991) one of
which is platelet-derived endothelial cell growth factor (PD-
ECGF) (Moghaddam et al., 1995).
PD-ECGF was initially cloned as a novel angiogenic
factor distinct from other known endothelial cell growth
factors by virtue of its unique sequence homology and lack of
heparin binding (Ishikawa et al., 1989). It was reported as
both chemotactic and mitogenic for endothelial cells and
angiogenic in several model systems (Ishikawa et al., 1989;
Haraguchi et al., 1994; Moghaddam et al., 1995). However,
recently PD-ECGF has been shown to be thymidine
phosphorylase (TP) (Barton et al., 1992; Furukawa et al.,
1992; Moghaddam and Bicknell, 1992; Usuki et al., 1992;
Finnis et al., 1993; Sumizawa et al., 1993). TP catalyses the
reversible phosphorolysis of thymidine to deoxyribose 1-
phosphate and thymine. TP is not a classic growth factor and
the mechanism by which TP promotes angiogenesis is
unknown. Nevertheless, some evidence suggests that metabo-
lites of TP might be responsible for its angiogenic activity
(Morris et al., 1989; Moghaddam and Bicknell, 1992;
Haraguchi et al., 1994).
Both mRNA and protein expression of TP have been
identified in human transformed cell lines and active enzyme
has also been detected in their conditioned media (Usuki et
al., 1989; Heldin et al., 1993). Transfection of TP into
transformed fibroblasts in nude mice results in increased
tumour vascularity (Ishikawa et al., 1989). In humans, areas
of increased blood flow as a measure of angiogenesis are
associated with elevated TP expression in ovarian tumours
(Reynolds et al., 1994). High levels of TP are not limited to
this tumour type but are also observed in liver, gastro-
intestinal, genitourinary and haematopoietic malignancies
(Zimmerman and Seidenberg, 1964; Kono et al., 1984;
Vertongen et al., 1984; Yoshimura et al., 1990). Indeed a
significant increase in TP has been detected in serum from
cancer patients (Pauly et al., 1977, 1978). However, many of
these studies have examined few cases and have relied on
tumour homogenates using different enzyme assays or
immunoblotting techniques. The cell type expressing this
metabolically important molecule is unknown. Furthermore,
its relationship to quantitative tumour angiogenesis, which
should help assess the importance of this candidate
angiogenic growth factor in breast cancer, has not been
examined.
Therefore, using an immunohistochemical approach the
aims of this study were to examine a large series of breast
carcinomas for (1) the incidence and cellular distribution of
TP protein; (2) the correlation between TP protein and
mRNA expression; (3) the relationship of TP protein
expression to other tumour variables including quantitative
angiogenesis; and (4) the prognostic utility of TP expression.
Materials and methods
Tumours and patients
A total of 240 breast carcinomas were taken from the
archival files of the John Radcliffe Hospital, Oxford. Patients
were treated by simple mastectomy or lumpectomy and
radiotherapy with axillary node sampling. All had axillary
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node status confirmed histologically. Grading was performed
according to the modified Bloom and Richardson method
(Elston, 1987). All tumours were stained for TP and a subset
of 185 was also assessed for vascularity. The characteristics of
these tumours are detailed in Table I.
Follow-up for all patients was conducted every 3 months
for the first 18 months, and every 6 months for 3 years. In all
patients adjuvant radiotherapy was administered to the
ipsilateral axilla if lymph nodes had histological evidence of
metastasis. Patients with confirmed recurrent disease were
treated by endocrine manipulation for soft tissue or skeletal
disease or by chemotherapy for visceral disease or failed
endocrine therapy. Patients with isolated soft tissue relapse
additionally received radiotherapy. Details of adjuvant
treatment consisting of cyclophosphamide, methotrexate
and 5-fluourouracil (CMF) are shown in Table I.
Oestrogen receptor and epidermal growth factor receptor
Oestrogen receptor (ER) content was determined using an
ELISA technique (Abbott Laboratories, USA). Tumours
were considered positive when ER levels exceeded
10 fmol mg-1 cytosolic protein. Epidermal growth factor
receptor (EGFR) was measured by ligand binding of [125I]1
EGF to tumour membranes. Concentrations greater than
20 fmol mg-1 membrane protein were considered positive as
previously reported (Needham et al., 1988; Horak et al.,
1992).
Immunohistochemistry
This was performed on formalin-fixed paraffin-embedded
sections cut onto coated slides. PG44c-recognising TP (Fox et
al., 1995a) and JC70 (Dako, UK) against CD31 (Parums et
al., 1990) were used before labelling by a standard
immunohistochemical technique. Predigestion with 12.5 mg
of protease type XXIV (Sigma, Poole, UK) per 100 ml of
phosphate-buffered saline (PBS) for 20 min at 37°C was
required for optimal JC70 immunostaining but no treatment
was necessary for TP.
Table I Clinicopathological characteristics of patients and tumours
Patient characteristic Number
Age (median, range) years 57(28- 82)
<50 70
>50 170
Surgical treatment
Lumpectomy 176
Simple mastectomy 64
Adjuvant treatment
Chemotherapy 56
Tamoxifen 135
Lymph nodes neg/pos 140/100
Tumour size (median, range) cm 2.2 (0.8-8)
<2 76
>2 164
Histology
Ductal 188
Lobular 25
Others 27
Grade
I 24
II 85
III 79
ERa (median, range) 21.2 (0-695)
<10 84
>10 156
EGFRa (median, range) 17.1 (0-210)
<20 130
>20 110
Survival follow-up (median, range) 36 (9-66) months
Deaths, recurrences 31, 48
afmol mg-I protein.
Assessment of TP expression and microvessel density
Tumours were assessed for TP by both the intensity and
proportion of cells staining. Intensity was semiquantitatively
placed into the following categories; 0, no staining; +, (score
1) weak; + +, (score 2) moderate; + + +, (score 3) strong
staining. Proportion of cells staining was placed into
categories of 0-24% (score 1), 25-74% (score 2) and
75-100% (score 3). Tumours were considered positive
(tumour class) for TP when more than 25% of the tumour
cells demonstrated moderate staining. The presence and
distribution of endothelial cell staining was also documented.
Vascular counts (VCs) were determined without knowl-
edge ofpatient outcome. The three most vascular areas where
the highest number of discrete microvessels were stained were
chosen by two observers over a conference microscope.
Microvessels were defined as any immunoreactive endothelial
cell(s) that was separate from adjacent microvessels. Vessels
within the sclerotic body of the tumour were not included.
These maximal areas of neovascularisation were identified by
scanning at low power ( x 40 and x 100). VCs were then
estimated by both observers using a 25-point Chalkley
eyepiece graticule at x 250 magnification (the graticule
covered an area of 0.155 mm2 at this magnification). The
graticule was rotated in the eyepiece to where the maximum
number of graticule dots overlay immunohistochemically
identified vessels or their lumens. VCs for individual tumours
were then produced using the mean of the three graticule
counts (Fox et al., 1995b).
Preparation of RNA
Total RNA was prepared by either the method of
Chomczyski and Sacchi or by guanidinium thiocyanate lysis
and caesium chloride gradient method from 64 tumours
(Sambrook et al., 1989) TP/PD-ECGF probe was generated
from plasmid pPL5 incorporating the full length cDNA of
TP/PD-ECGF. This was digested with NcoI and the 5'
overhangs were end-filled using DNA polymerase 1 (Klenow
fragment) before further digestion with BamHl. The 241 bp
fragment produced corresponded to 817-1058 base pairs of
the coding region for TP/PD-ECGF. This was cloned into
the EcoRV/BamH1 sites of pBluescript SK+. The resultant
construct was linearised with HindIII before generation of an
anti-sense transcript with T3 RNA polymerase.
Ribonuclease protection analysis
Radiolabelled riboprobes were synthesised that incorporated
[OC-32P]CTP from linearised plasmid DNA by in vitro
transcription (Sambrook et al., 1989). Anti-sense probes
were hybridised to 10 jug of total cellular RNA and free
unhybridised probe removed by digestion with RNAase Tl
and RNAase A. Protected fragments were analysed by
electrophoresis in 5% polyacrylamide/urea sequencing gels
followed by autoradiography. In each hybridisation an anti-
sense transcript corresponding to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) transcribed from a con-
struct was included as an internal control. Transfer RNA
was used as a negative control. mRNA was quantified by
scanning laser densitometry (Bioimage Densitometer, Milli-
pore) and signals normalised to the GAPDH control to
provide a standard.
Statistics
Chi-square tests were used to investigate the relationship
between the different parameters stratified by the cut-off
points outlined above. Survival curves were plotted using
the method of Kaplan and Meier (1958) and the log-rank
test to determine statistical differences between life tables.
The statistical analysis was performed using the Stata
package release 3.1 (Stata Corporation, College Station,
TX, USA).Results
Immunohistochemistry
Tumour cells were positive for TP/PD-ECGF in 113/240
(47%) cases of breast cancer (Figure 1). The usual pattern of
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immunoreactivity was both nuclear and cytoplasmic but
occasionally only one of these was present. Immunoreactivity
was heterogeneous, occasionally focal and often up-regulated
at the infiltrating tumour edge (Figure 1). Staining was also
seen in some cases of ductal carcinoma in situ (DCIS)
Figure 1 (PG44c streptavidin-biotin immunoperoxidase-DAB). Intense staining of (a) an infiltrating ductal and (b) an infiltrating
lobular carcinoma with moderate staining of inner ductal epithelium of entrapped normal breast. (c) Immunoreactivity in DCIS
with negative invasive element. (d) Negative DCIS. (e) Accentuation of staining at the invading tumour edge. (f) Positive nuclear
staining adjacent to areas of necrosis. (g) Cytoplasmic without nuclear immunostaining of invasive carcinoma. (h) Prominant
endothelial cell reactivity in negative invasive carcinoma. Negative ductal carcinomas with positive macrophage infiltrate (i) and
stroma (j).Thymidine phosphorylase in breast cancer
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elements, although this positivity was independent of any
adjacent invasive component labelled (Figure 1). Increased
TP positivity was sometimes but not always seen adjacent to
regions of tumour necrosis (Figure 1). Immunostaining was
often present in the stroma and tumour associated
macrophages. Endothelial cell reactivity was also observed
in 146 (61%) of these cases (Figure 1). This was usually focal
at the periphery of the tumour and associated with
inflammatory cells, although positivity was also present
within the tumour body. Occasionally widespread endothe-
lial cell staining was observed. Normal breast epithelial
elements surrounding or entrapped by tumour demonstrated
weak to moderate immunoreactivity of the inner ductal
epithelial cells; the myoepithelial element was negative.
A total of 185 tumours were also assessed for tumour
vascularity. Homogeneous intensity of CD31 endothelial cell
staining was observed in individual tumours. Vascularity
ranged from 3-10 Chalkley counts per x 250 magnification
(median 6).
Relationship between ribonuclease protection and
immunohistochemistry
Densitometry normalised for GAPDH in 64 cases showed
that TP expression ranged from 3-231 (median 32). Plotting
this data demonstrated a logarithmic distribution. Therefore
a log transformation was performed. Log expression ranged
from 1.09 to 5.44 (median 3.46). Pairwise correlation between
the log-transformed protection data and the tumour class (i.e.
those tumours considered positive for TP) demonstrated no
significant correlation (t-test t= 1.9 P=0.06). However, there
was a weak but significant correlation (r=0.33 P=0.02)
(Figure 2) between log-transformed protection data and a
combined immunohistochemistry score (defined as the sum of
staining intensity score and proportion of tumour stained).
Relationship of TP protein to Chalkley count and other
prognostic variables
The ranges and medians together with the categories for age,
histology, size, nodal status, ER and EGFR used for
statistical analysis are summarised in Table I. There was no
significant correlation between TP expression and Chalkley
count (chi-square 2.47 P=0.12) or between Chalkley count
and the presence of endothelial cell staining (chi-square 0.46
P=0.5). Significant inverse correlations were observed
between TP expression and tumour grade (chi-square 6.04
P=0.05) and tumour size (chi-square 8.99 P=0.003). There
was no significant correlation in tumours <2 cm between
Chalkley count and tumour TP expression (chi-square 1.13
P=0.28). No correlation was present between TP and patient
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age (chi-square 0.71 P=0.4), lymph node status (chi-square
1.14 P=0.28), ER status (chi-square 0.015 P=0.9), EGFR
status (chi-square 1.19 P=0.28) or tumour histology (chi-
square 2.02 P=0.37).
Relationship of TP expression to survival
There was no significant difference in relapse-free survival or
overall survival in a univariate analysis of all patients
(P=0.11 and P=0.34 respectively) (Figure 3), or node-
negative patients only (P=0.59 and P=0.66 respectively).
However, in node-positive subgroups there was a significant
improvement in relapse-free survival in patients with elevated
tumour TP (P=0.05) (TP negative, no CMF, n=29; TP
positive, no CMF, n=27; TP negative, CMF, n= 11; TP
positive, CMF n=24). There was only a trend that did not
reach significance for overall survival in this group (P=0.07)
(Figure 4).
Discussion
In this study we have demonstrated up-regulation of TP in
breast cancers by both ribonuclease protection assay (RPA)
and immunohistochemistry. Since TP by RPA measures all
tumour elements, we observed no significant correlation to
TP tumour class (i.e. more than a score of 2+ staining for
intensity in more than 25% of the tumour). However, by
accounting for the sum of the variation in epithelial element
within individual tumours and comparing immunohistochem-
istry score (sum of the proportion of cells stained and their
intensity) to RPA, a weak but significant correlation was
observed. Since individual tumours also have a varied
amount of stroma and inflammatory infiltrate, we were not
able to satisfactorily quantitate the stromal and inflammatory
cell elements. Nevertheless, TP expression appears to be
regulated mainly by transcription and not by post-transla-
tional mechanisms.
TP neoplastic cell expression was often heterogeneous and
was observed in both DCIS and invasive elements, although
their expression appeared independent. Tumour TP expres-
sion was usually both nuclear and cytoplasmic but nuclear or
cytoplasmic immunoreactivity was also observed, suggesting
a variety of roles for TP in tumour cell metabolism. Its
nuclear location might indicate a role of regulating thymidine
levels for DNA synthesis, while its cytoplasmic location
might be required to regulate other enzymes like thymidylate
synthetase, thymidine kinase and ribonucleotide reductase.
Endothelial cell TP expression, although focal, was
observed in a significant proportion of tumours and was
most prominent at the tumour periphery. This is an area
0.8
8
$
$ 8
16
01)
.0
0
0~
0.6
0.4
0.2
r = 0.33
0 2 4 6 8
TP immunohistochemistry score
Figure 2 Graphs plotted for TP log ribonuclease protection and
tumour score.
o
....... e~~I.....
- TP:positive
TP negative
P= 0.1
0 12 24 36 48 60 72
Survival time (months)
Figure 3 Relapse-free survival plotted for TP expression for all
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Figure 4 Relapse-free survival (a) and overall survival (b) plotted
for TP expression for node-positive patients.
where tumour angiogenesis is most active (Fox et al., 1993)
and suggests that TP also has an important role in
endothelial cell metabolism. However, we observed no
significant correlation between tumour TP expression and
tumour vascularity. Although this might suggest that TP is
not a significant angiogenic factor in breast carcinoma, TP
might be important early in tumour angiogenesis through
remodelling of the existing vasculature. After this initial step
other angiogenic factors might then assume more signifi-
cance. This sequence would also explain the high expression
of TP in small tumours of low grade. Furthermore, this is in
accordance with the increase in tumour size but not
microvessel density in mouse xenografts of MCF-7 breast
carcinoma cells transfected with TP over controls (Mo-
ghaddam et al., 1995). In both instances TP appears to alter
the rate of vascularisation, consistent with TP being
chemotactic but non-mitogenic for endothelium (Ishikawa
et al., 1989; Miyazono and Takaku, 1991; Haraguchi et al.,
1994). Nevertheless we did not observe a significant
correlation between tumour vascularity and TP in tumours
<2 cm.
Accentuation of TP was often present at the infiltrating
tumour margin and adjacent to areas of tumour necrosis,
both situations in which release of angiogenic factors would
be anticipated. Indeed in necrotic tumour regions in which
tumour cell immunoreactivity was absent, up-regulation of
TP in non-neoplastic elements was observed. Thus, although
presently not demonstrated, TP, like vascular endothelial
growth factor, a potent angiogenic factor, might also be
modulated by hypoxia (Shweiki et al., 1992). Nevertheless, in
tumour cell lines it has been shown that tumour necrosis
factor oc, interleukin 1 and interferon y up-regulate TP (Ho et
al., 1990; Eda et al., 1993) and therefore in vivo through
autocrine and paracrine pathways tumours might directly
regulate their TP expression. Furthermore, cytokines might
also recruit macrophages (O'Sullivan et al., 1993) rich in TP
which may themselves also, through paracrine loops,
augment tumour cell TP. Dedifferentiated tumours that
show loss of cognate receptors (e.g. interleukin 4, data not
shown) would be unable to use these networks, which would
also account for the low levels of TP observed in high-grade
tumours.
Although no significant reduction in relapse-free survival
or overall survival was observed in all patients or the node-
negative subgroup, there was a significantly higher relapse-
free survival and borderline significance for overall survival in
node-positive patients with TP-positive tumours. This may be
due to TP modulating the sensitivity of tumour cells to drugs
widely used in adjuvant therapy in this patient group. It
might both metabolise 5-fluorouracil to its active form and
also, by degrading thymidine, enhance sensitivity to
methotrexate. This has been demonstrated in vitro by
transfection of TP into the MCF-7 breast carcinoma cell
line, which increases its sensitivity to 5-deoxy-5-fluorouridine
over 150-fold (Patterson et al., 1995). Therefore, tumour
levels of TP might give some indication of the predictive
response to some chemotherapeutic agents. Furthermore,
since TP is up-regulated by several cytokines, anti-tumour
activity of similar agents might also be therapeutically raised
in TP-poor tumours.
Future studies are now directed at exploring these
observations by examining the regulation of TP expression
and attempting to correlate tumour response rates with
chemotherapeutic agents to determine whether patient
response can be predicted or enhanced by other agents.
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